Omeros Corp OMER
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros Gets FDA Approval of Yartemlea
Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion — Update
Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

